Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Stayble Therapeutics: BioStock: Great interest at conferences for Stayble's treatment

Stayble Therapeutics

Stayble Therapeutics has recently returned from the European Congress on Clinical Trials in Pain in Vienna where the progress in the clinical phase IIb study with STA363 for the treatment of degenerative disc disease was presented. During the autumn, the company has also participated in several partnering events, most recently BIO-Europe in Leipzig, to find potential partners for phase III. BioStock contacted the company's CEO Andreas Gerward and CSO Anders Lehmann to get to know more about the interest in STA363 and their learnings from the events.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/12/great-interest-at-conferences-for-staybles-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.